Meningococcal disease and ciprofloxacin: PGD template
Patient group direction (PGD) template to supply or administer ciprofloxacin for meningococcal disease clusters in educational or residential settings.
Applies to England
Documents
Details
This patient group direction (PGD) supports the supply or administration of ciprofloxacin to adults and children for the management of clusters of meningococcal disease, when 2 or more cases are reported in a congregate or other closed setting. PGD version 05.00 is valid from 20 October 2025 to 19 October 2028
It can be used when a decision has been made by an experienced member of the UK Health Security Agency Health Protection Team or by the Incident Management Team to offer chemoprophylaxis, for example, to:
- educational settings (nursery, primary, secondary schools)
- care homes
- military barracks
The PGD template requires further authorisation by a clinical governance or patient safety lead who has designated responsibility for signing PGDs. It is not legal or valid without this local, formal authorisation.
The authorising commissioning body and providers are responsible for the adoption and governance of use of this PGD. Provider organisations and health professionals should check they are using the current version and only work to a legally authorised PGD from their commissioning body.
Updates to this page
-
Updated PGD version 05.00, which is valid from 20 October 2025 to 19 October 2028.
-
Added version 04.00 see page 2 for changes.
-
Added new version of PGD template.
-
Updated 'Meningococcal disease: PGD template for the supply or administration of ciprofloxacin'.
-
First published.